ALDX - アルデイラ・セラピュ―ティクス （Aldeyra Therapeutics Inc.）

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the completion of enrollment in the Phase 2 clinical trial of the orally administered RASP modulator ADX-629, an investigational new drug, for the treatment of chronic cough. The multicenter, randomized, double-blind, placebo-controlled, two-period Phase 2 crossover trial enrolled 51 patients with refractory or unexplained chronic cough, which is often defined as a cough that persists for more

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the completion of enrollment in the Phase 2 clinical trial of ADX‑2191 (methotrexate injection, USP), an investigational drug candidate, for the treatment of retinitis pigmentosa, a group of rare genetic eye diseases characterized by retinal cell death and loss of vision, for which there is no U.S. Food and Drug Administration (FDA)-approved treatment. The open-label, single-center Phase 2 cli

Aldeyra Therapeutics, Inc. (NASDAQ:NASDAQ:ALDX) Q4 2022 Earnings Conference Call March 9, 2023 8:00 AM ETCompany ParticipantsBruce Greenberg - Interim Chief Financial OfficerTodd Brady -…

Aldeyra Therapeutics press release (ALDX): FY GAAP EPS of -$1.06 beats by $0.10.Cash, Cash Equivalents, and Marketable Securities of $174.3 Million as of December 31, 2022

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today reported recent corporate highlights and financial results for the year ended December 31, 2022. “Now with Priority Review Designation for the treatment of primary vitreoretinal lymphoma, ADX‑2191 joins reproxalap as the second investigational drug candidate at Aldeyra under ND

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the completion of enrollment in the Phase 2 clinical trial of the orally administered RASP modulator ADX-629, an investigational new drug, for the treatment of chronic cough. The multicenter, randomized, double-blind, placebo-controlled, two-period Phase 2 crossover trial enrolled 51 patients with refractory or unexplained chronic cough, which is often defined as a cough that persists for more

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the completion of enrollment in the Phase 2 clinical trial of ADX‑2191 (methotrexate injection, USP), an investigational drug candidate, for the treatment of retinitis pigmentosa, a group of rare genetic eye diseases characterized by retinal cell death and loss of vision, for which there is no U.S. Food and Drug Administration (FDA)-approved treatment. The open-label, single-center Phase 2 cli

Aldeyra Therapeutics, Inc. (NASDAQ:NASDAQ:ALDX) Q4 2022 Earnings Conference Call March 9, 2023 8:00 AM ETCompany ParticipantsBruce Greenberg - Interim Chief Financial OfficerTodd Brady -…

Aldeyra Therapeutics press release (ALDX): FY GAAP EPS of -$1.06 beats by $0.10.Cash, Cash Equivalents, and Marketable Securities of $174.3 Million as of December 31, 2022

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today reported recent corporate highlights and financial results for the year ended December 31, 2022. “Now with Priority Review Designation for the treatment of primary vitreoretinal lymphoma, ADX‑2191 joins reproxalap as the second investigational drug candidate at Aldeyra under ND

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) closed Thursday at $6.16 per share, up from $5.60 a day earlier. While Aldeyra Therapeutics Inc. has overperformed by 10.00%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ALDX fell by -16.53%, with highs and lows ranging from $7.99 to $2.36, whereas […]

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that, following the recent receipt of official minutes from its pre-NDA (New Drug Application) meeting with the U.S. Food and Drug Administration (FDA), the Company plans to submit an NDA as soon as the end of 2022 for marketing approval of the investigational drug candidate ADX-2191 for the treatment of primary vitreoretinal lymphoma. “Pending FDA review, ADX-2191 could be the first FDA-appro

Aldeyra Therapeutics (ALDX) on Tuesday said it had submitted a new drug application to the U.S. FDA for its investigational drug reproxalap for the treatment of dry eye disease symptoms

https://www.investing.com/news/pro/aldeyra-therapeutics-pt-lowered-to-23-at-citi-432SI-2949775

The share price of Aldeyra Therapeutics Inc. (NASDAQ:ALDX) rose to $5.50 per share on Thursday from $5.18. While Aldeyra Therapeutics Inc. has overperformed by 6.18%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ALDX fell by -39.49%, with highs and lows ranging from $9.35 to $2.36, […]